Apolipoprotein B100 is a suppressor of Staphylococcus aureus-induced innate immune responses in humans and mice

European Journal of Immunology

Volumn 42, Issue 11, 2012, Pages 2983-2989

  Sigel, Stefanie ^a,b   Bunk, Sebastian ^c   Meergans, Thomas ^c   Doninger, Bianca ^a,b   Stich, Karin ^b   Stulnig, Thomas ^b   Derfler, Kurt ^b   Hoffmann, Julia ^c   Deininger, Susanne ^c   von Aulock, Sonja ^c   Knapp, Sylvia ^a,b  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Apolipoprotein B100; Innate immune response; Staphylococcus aureus

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B100; LIPOTEICHOIC ACID; LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APHERESIS; ARTICLE; BLOOD ANALYSIS; CHROMATOGRAPHY; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; APOLIPOPROTEIN B-100; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; IMMUNITY, INNATE; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPECIFIC PATHOGEN-FREE ORGANISMS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICHOIC ACIDS;

EID: 84868094450     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242564     Document Type: Article

References (31)

1. Brautbar, A. and Ballantyne, C. M., Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nat. Rev. Cardiol. 2011. 8: 253-265.
2. Khovidhunkit, W., Kim, M. S., Memon, R. A., Shigenaga, J. K., Moser, A. H., Feingold, K. R. and Grunfeld, C., Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 2004. 45: 1169-1196.
3. David, M. Z. and Daum, R. S., Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 2010. 23: 616-687.
4. Morath, S., Geyer, A. and Hartung, T., Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J. Exp. Med. 2001. 193: 393-397.
5. Bubeck Wardenburg, J., Williams, W. A. and Missiakas, D., Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins. Proc. Natl. Acad. Sci. USA 2006. 103: 13831-13836.
6. Kang, J. Y., Nan, X., Jin, M. S., Youn, S. J., Ryu, Y. H., Mah, S., Han, S. H. et al., Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 2009. 31: 873-884.
7. Takeuchi, O., Hoshino, K. and Akira, S., Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J. Immunol. 2000. 165: 5392-5396.
8. Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath, S. et al., CD36 is a sensor of diacylglycerides. Nature 2005. 433: 523-527.
9. Schroder, N. W., Morath, S., Alexander, C., Hamann, L., Hartung, T., Zahringer, U., Gobel U.B. et al., Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 2003. 278: 15587-15594.
10. Barcia, A. M. and Harris, H. W., Triglyceride-rich lipoproteins as agents of innate immunity. Clin. Infect. Dis. 2005. 41 Suppl 7: S498-S503.
11. Feingold, K. R. and Grunfeld, C., The role of HDL in innate immunity. J. Lipid Res. 2011. 52: 1-3.
12. Peterson, M. M., Mack, J. L., Hall, P. R., Alsup, A. A., Alexander, S. M., Sully, E. K., Sawires, Y. S. et al., Apolipoprotein B is an innate barrier against invasive Staphylococcus aureus infection. Cell. Host Microbe. 2008. 4: 555-566.
13. Bhakdi, S., Tranum-Jensen, J., Utermann, G. and Fussle, R., Binding and partial inactivation of Staphylococcus aureus alpha-toxin by human plasma low density lipoprotein. J. Biol. Chem. 1983. 258: 5899-5904.
14. Grunfeld, C., Marshall, M., Shigenaga, J. K., Moser, A. H., Tobias, P. and Feingold, K. R., Lipoproteins inhibit macrophage activation by lipoteichoic acid. J. Lipid Res. 1999. 40: 245-252.
15. Mueller, M., Stamme, C., Draing, C., Hartung, T., Seydel, U. and Schromm, A. B., Cell activation of human macrophages by lipoteichoic acid is strongly attenuated by lipopolysaccharide-binding protein. J. Biol. Chem. 2006. 281: 31448-31456.
16. Knapp, S., von Aulock, S., Leendertse, M., Haslinger, I., Draing, C., Golenbock, D. T. and van der Poll, T., Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J. Immunol. 2008. 180: 3478-3484.
17. Hashimoto, M., Furuyashiki, M., Kaseya, R., Fukada, Y., Akimaru, M., Aoyama, K., Okuno, T. et al., Evidence of immunostimulating lipoprotein existing in the natural lipoteichoic acid fraction. Infect Immun. 2007. 75: 1926-1932.
18. Stoll, H., Dengjel, J., Nerz, C. and Gotz, F., Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect. Immun. 2005. 73: 2411-2423.
19. Bunk, S., Sigel, S., Metzdorf, D., Sharif, O., Triantafilou, K., Triantafilou, M., Hartung, T. et al., Internalization and coreceptor expression are critical for TLR2-mediated recognition of lipoteichoic acid in human peripheral blood. J. Immunol. 2010. 185: 3708-3717.
20. Levels, J. H., Abraham, P. R., van Barreveld, E. P., Meijers, J. C. and van Deventer, S. J., Distribution and kinetics of lipoprotein-bound lipoteichoic acid. Infect. Immun. 2003. 71: 3280-3284.
21. Segrest, J. P., Jones, M. K., De Loof, H. and Dashti, N., Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 2001. 42: 1346-1367.
22. Shor, R., Wainstein, J., Oz, D., Boaz, M., Matas, Z., Fux, A. and Halabe, A., Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy. Ann. Clin. Lab. Sci. 2007. 37: 343-348.
23. Ginsburg, I., Role of lipoteichoic acid in infection and inflammation. Lancet. Infect. Dis. 2002. 2: 171-179.
24. Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E. and Herz, J., Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 1993. 92: 883-893.
25. Netea, M. G., Demacker, P. N., Kullberg, B. J., Boerman, O. C., Verschueren, I., Stalenhoef, A. F. and van der Meer, J. W., Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J. Clin. Invest. 1996. 97: 1366-1372.
26. Jiao, Y. L. and Wu, M. P., Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 2008. 43: 83-87.
27. Morath, S., Geyer, A., Spreitzer, I., Hermann, C. and Hartung, T., Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect. Immun. 2002. 70: 938-944.
28. Bartolome, N., Arteta, B., Martinez, M. J., Chico, Y. and Ochoa, B., Kupffer cell products and interleukin 1beta directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes. Innate Immun. 2008. 14: 255-266.
29. Bartolome, N., Rodriguez, L., Martinez, M. J., Ochoa, B. and Chico, Y., Upregulation of apolipoprotein B secretion, but not lipid, by tumor necrosis factor-alpha in rat hepatocyte cultures in the absence of extracellular fatty acids. Ann. NY Acad. Sci. 2007. 1096: 55-69.
30. Draing, C., Traub, S., Deininger, S., Mang, P., Moller, H. M., Manso, M., Rossi, F. et al., Polypropylene glycol is a selective binding inhibitor for LTA and other structurally related TLR2 agonists. Eur. J. Immunol. 2008. 38: 797-808.
31. Thompson, G. R., Catapano, A., Saheb, S., Atassi-Dumont, M., Barbir, M., Eriksson, M., Paulweber, B. et al., Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr. Opin. Lipidol. 2010. 21: 492-498.